Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 10,331 Shares

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 10,331 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $3.15, for a total value of $32,542.65. Following the transaction, the chief executive officer now owns 3,775,019 shares of the company’s stock, valued at $11,891,309.85. The trade was a 0.27 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Checkpoint Therapeutics Trading Down 3.1 %

Shares of NASDAQ:CKPT opened at $3.13 on Wednesday. The company has a 50 day moving average of $3.39 and a 200 day moving average of $2.99. The stock has a market cap of $152.84 million, a P/E ratio of -1.70 and a beta of 1.36. Checkpoint Therapeutics, Inc. has a 12 month low of $1.38 and a 12 month high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). On average, equities analysts forecast that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Checkpoint Therapeutics

Several large investors have recently added to or reduced their stakes in CKPT. Virtu Financial LLC increased its stake in Checkpoint Therapeutics by 180.5% in the 4th quarter. Virtu Financial LLC now owns 38,157 shares of the company’s stock worth $122,000 after acquiring an additional 24,552 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Checkpoint Therapeutics during the fourth quarter worth about $67,000. Charles Schwab Investment Management Inc. bought a new position in shares of Checkpoint Therapeutics in the fourth quarter worth approximately $64,000. SBI Securities Co. Ltd. purchased a new stake in Checkpoint Therapeutics in the fourth quarter valued at approximately $32,000. Finally, PUREfi Wealth LLC bought a new stake in Checkpoint Therapeutics during the fourth quarter valued at approximately $32,000. Institutional investors own 22.00% of the company’s stock.

Analyst Ratings Changes

CKPT has been the subject of a number of research reports. D. Boral Capital began coverage on shares of Checkpoint Therapeutics in a research report on Monday, January 13th. They set a “buy” rating and a $9.00 target price for the company. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday, December 16th. Finally, Lake Street Capital raised their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, December 16th.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.